Literature DB >> 3970856

Heterogeneity of hereditary and acquired factor X deficiencies by combined immunochemical and functional analyses.

D S Fair, T S Edgington.   

Abstract

Limited information is available regarding molecular abnormalities associated with derived factor X deficiencies. In order to assess the types of molecular aberrations that may occur in this group of haemostatic diseases we have analysed plasmas of 33 individuals from 28 kindred exhibiting factor X deficiency. These included those of hereditary type, transiently acquired deficiency as well as factor X deficiency associated with amyloidosis. Plasmas were analysed by one-stage assays for factor X activation by the extrinsic coagulation pathway, intrinsic coagulation pathway and Russell's viper venom. Selected plasmas were analysed in two-stage assays. Normal factor X concentration by specific radioimmunoassay was 6.38 +/- 1.29 micrograms/ml. Factor X associated with factor X deficiency were grouped by their specific activities measured for the three activation pathways and antigen concentration. The results suggest that a broad spectrum of molecular aberrations exist in the factor X deficiency states. The most common group of factor X deficiency was associated with abnormal activation of factor X by all three pathways. Variants of factor X associated with primary amyloidosis and transient acquired deficiency appeared to be abnormal molecules and not just reduced factor X concentration. Hereditary abnormal factor X molecules include the spectrum of potential defective molecules. The relationship of factor X structure to function and the heterogeneity of these defective molecules is discussed.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3970856     DOI: 10.1111/j.1365-2141.1985.tb02990.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  2 in total

1.  Treatment with cerivastatin in primary mixed hyperlipidemia induces changes in platelet aggregation and coagulation system components.

Authors:  A Ugur Ural; M Ilker Yilmaz; Ferit Avcu; Atilla Yalcin
Journal:  Int J Hematol       Date:  2002-10       Impact factor: 2.490

2.  Factor XSanto Domingo. Evidence that the severe clinical phenotype arises from a mutation blocking secretion.

Authors:  H H Watzke; A Wallmark; N Hamaguchi; P Giardina; D W Stafford; K A High
Journal:  J Clin Invest       Date:  1991-11       Impact factor: 14.808

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.